sellWeak cluster of 210b5-1 plan
Andrew Obenshain sold $2,555 of BLUE
President and CEO at bluebird bio, Inc.. 807 shares at an average of $3.17, traded Nov 3, 2023, filed Nov 3, 2023.
Warning score
13Value
$2,555
807 shares
Holdings after
291,134
-0% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +25RoleCEO
- 0Trade size$3k at market
- 0Share of holdings soldSold 0.3% of holdings
- +8Cluster2 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001562180-23-007552, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 3, 2023 | SOpen-market sale Common Stock10b5-1 | -807 | $3.17 | $2,555 | 291,134 | Nov 3, 2023 |
Related signals
Other insiders at bluebird bio, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 3Weak | bluebird bio, Inc. | Richard A Colvin Chief Medical Officer | $2,289 584 shares | -7% | |
| 3Weak | bluebird bio, Inc. | Thomas J Klima See Remarks | $1,960 500 shares | -6% | |
| 3Weak | bluebird bio, Inc. | Richard A Colvin Chief Medical Officer | $473 64 shares | -1% | |
| 3Weak | bluebird bio, Inc. | Thomas J Klima See Remarks | $902 122 shares | -1% | |
| 0Weak | bluebird bio, Inc. | Richard A Colvin Chief Medical Officer | $176 19 shares | -0% | |
| 3Weak | bluebird bio, Inc. | Richard A Colvin Chief Medical Officer | $1,178 2,824 shares | -2% | |
| 13Weak | bluebird bio, Inc. | Andrew Obenshain President and CEO | $405 971 shares | -0% | |
| 2Weak | bluebird bio, Inc. | Christopher Krawtschuk Chief Financial Officer | $20k 4,526 shares | -9% | |
| 3Weak | bluebird bio, Inc. | Richard A Colvin Chief Medical Officer | $6,975 2,343 shares | -2% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.